Europe dry eye syndrome treatment market is projected to register a substantial CAGR of in the forecast period 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026

Market Segmentation

By Product Type (Tear stimulators, Artificial tears, Secretagogue, Others), Dosage Type ( Liquid, Semi-solid, Others), Drug Class( Lubricating Agents, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Dose(Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), End Users (Home Healthcare, Hospitals, Clinics, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe).
Some of the major factors contributing to the growth of the Europe dry eye syndrome treatment market:

? Increasing research and development
? Changing demographical trends to drive the market

Market Players

The key market players for Europe dry eye syndrome treatment market are listed below:
? ALLERGAN
? Bausch & Lomb Incorporated
? Novartis AG
? Johnson & Johnson Services, Inc.
? Prestige Consumer Healthcare, Inc.
? AKORN, INC.
? Sun Pharmaceutical Industries Ltd.
? Teva Pharmaceutical Industries Ltd.
? Novaliq GmbH
? Santen Pharmaceutical Co., Ltd.,
? Cardinal Health
? Alembic Pharmaceuticals Limited.
? Cipla Inc.
? Perrigo Company plc
? SENJU PHARMACEUTICAL CO. LTD.
? Horus Pharma
? ROHTO Pharmaceutical Co., Ltd.
? VISUfarma
? Hubrx